About this trial

Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial.

Clinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.

Eligibility criteria

Qualifiers

Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension

Disqualifiers

Withdrawal of written informed consent

Trial design

Treatments tested in this trial

  • Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)

Treatment groups

2,000 Participants
are divided into 1 treatment group

Locations

1
University Medical Center Freiburg, Department of Medicine II79106, Freiburg im Breisgau Germany

Sponsors and collaborators

University Hospital Freiburg

Lead sponsor